Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

T Barbui,J Thiele,A Carobbio,I Bertozzi,G Finazzi,E Rumi,A Rambaldi,H Gisslinger,M Ruggeri,S Betti,A Tefferi,F Rodeghiero,V Buxhofer-Ausch,M L Randi,C Falcone,V De Stefano,F Passamonti,A M Vannucchi

doi:10.1038/bcj.2015.94

Abstract

Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia.

Highlights

Current risk stratification for thrombosis in essential thrombocythemia (ET) is two-tiered and considers low- and high-risk categories based on the respective absence or presence of either age 460 years or history of thrombosis.[1]
In the recent International Prognostic Score for Thrombosis in ET (IPSETthrombosis), age and history of thrombosis were confirmed as independent risk factors for future thrombosis and the study identified independent prothrombotic role for cardiovascular (CV) risk factors and JAK2V617F mutation.[2]
1019 patients were selected in whom JAK2 mutational status was available

Summary

LETTER TO THE EDITOR

Blood Cancer Journal (2015) 5, e369; doi:10.1038/bcj.2015.94; published online 27 November 2015. Current risk stratification for thrombosis in essential thrombocythemia (ET) is two-tiered and considers low- and high-risk categories based on the respective absence or presence of either age 460 years or history of thrombosis.[1] In the recent International Prognostic Score for Thrombosis in ET (IPSETthrombosis), age and history of thrombosis were confirmed as independent risk factors for future thrombosis and the study identified independent prothrombotic role for cardiovascular (CV) risk factors and JAK2V617F mutation.[2] This model outperformed the two-tiered conventional risk stratification in predicting future vascular events and was not further affected by the recently discovered CALR mutation.[3] In the current study, we re-analyzed the original IPSET-thrombosis data in 1019 patients with WHOdefined ET in whom JAK2 mutational status was available, to quantify the individual contributions of JAK2 mutations and CV risk factors in conventionally assigned low- and high-risk ET. The revised risk stratification scheme might include

High risk

Findings

Cardiovascular risk factor